17P - Can subtyping diagnosis help in optimizing the management of lung adenocarcinoma patients?
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
T.T. Kondratieva1, N. Velizheva2, M.V. Dardyk3, A. Pavlovskaya4, N. Mazurenko5, I. Tsyganova5, S. Subramanian6
In the era of targeted therapy of metastatic and locally advanced lung cancer (LC) the final verdict already often belongs to genetists. Is it reasonable to do molecular screening for 80% of LC that are NSCLC? Are the advantages worth the price of research? Are there any correlations between molecular changes, morphological features of different histological subtypes, clinical implications and prognosis of disease? 1. To evaluate the need and clinical significance of subtyping lung cancer adenocarcinomas (AC) on small biopsies and cytological samples in daily practice 2. To analyze the correlation between histologic subtypes of Lung AC, EGFR/KRAS-status and efficiency of the treatment in LC patients.